Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1. (Original) A method for a physical pre-treatment of an active substance, characterized in that it comprises adding a poor solvent or a mixture of solvents to the active substance or to a mixture of the active substance with other excipients, the solubility of the substance in said solvent being less than 0.1 g/L, followed by drying.

Claim 2. (Original) A method for a physical pre-treatment of an active substance according to claim 1, characterized in that said method comprises humidifying with water.

Claim 3. (Original) A method for a physical pre-treatment of an active substance according to claim 2, characterized in that the aqueous solution may contain various pharmaceutically acceptable excipients such as binders, buffers, emulgators, surfactants and others.

Claim 4. (Original) A method for a physical pre-treatment of an active substance according to claim 1, characterized in that the part of the active substance in the mass of the whole formulation is over about 30%.

Claim 5. (Original) A method for a physical pre-treatment of an active substance according to claim 1, characterized in that the part of the active substance in the mass of the whole formulation is over about 40%.

Claim 6. (Original) A method for a physical pre-treatment of an active substance according to claim 1, characterized in that the active substance is practically insoluble in the solvent used.

Claim 7. (Original) A method for a physical pre-treatment of an active substance according to claim 6, characterized in that the solvent used is water, wherein the solubility of the active substance is under about 0.1 g/L.

Claim 8. (Original) A method for a physical pre-treatment of an active substance according to claim 1, characterized in that the active substance, if micronized, is difficult to be directly tabletted or encapsulated.

Claim 9. (Original) A method for a physical pre-treatment of an active substance according to claim 1, characterized in that the particles thereof are large, brittle and/or porous.

Claim 10. (currently amended) A method for a physical pre-treatment of an active substance according to claim~~s~~ 1 ~~to 9~~, characterized in that the active substance is clarithromycin.

Claim 11. (Original) A method for a physical pre-treatment of an active substance according to claim 10, characterized in that clarithromycin is micronized.

Claim 12. (Original) A method for a physical pre-treatment of an active substance according to claim 11, characterized in that the pre-treated, micronized clarithromycin enters a direct mixture for tabletting or encapsulating as a starting material.

Claim 13. (currently amended) A method for a physical pre-treatment of an active substance according to claims ~~1 to~~ 12, characterized in that the obtained cores are coated.

Claim 14. (Original) A method for a physical pre-treatment of an active substance according to claim 13, characterized in that the coating also contains a polymer having viscosity of up to about 15 mPas.

Claim 15. (Original) A method for a physical pre-treatment of an active substance according to claim 14, characterized in that the coating contains at least about 10% of a polymer having viscosity of up to about 15 mPas.

Claim 16. (currently amended) A method for a physical pre-treatment of an active substance according to claims 14 ~~and 15~~, characterized in that the polymer used in the coating has a viscosity of over about 6 mPas.

Claim 17. (currently amended) A pharmaceutical formulation with clarithromycin or analogues thereof, characterized in that the active substance is modified according to the method of claims 1 ~~to 16~~.

Claim 18. (currently amended) A pharmaceutical formulation prepared according to the method of claims 1 ~~to 16~~ for use in medicine for the treatment and prevention of diseases.

Claim 19. (currently amended) The use of a film coating composed of a combination of polymers having viscosities of up to about 15 mPas and about 6 mPas for coating tablet cores manufactured according to the method of claims ~~1 to~~ 12.